Trial Profile

A first in human phase IB open label study of CLB-3000

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CLB-3000 (Primary)
Indications Hepatitis B
Focus Adverse reactions; First in man
Sponsors ClearB Therapeutics

Most Recent Events

12 Oct 2023 According to a ClearB Therapeutics media release, the first patient has been dosed in the Phase 1b clinical study evaluating the therapeutic vaccine CLB-3000. Satisfactory review of safety data for this patient supported opening enrollment for the remainder of the cohort. Results from the two ascending dose cohorts are expected in 2H 2024.
12 Oct 2023 Status changed from planning to recruiting, according to a ClearB Therapeutics media release.
31 Oct 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com